ProQR Therapeutics N.V logo

PRQR

ProQR Therapeutics N.V

$0.83

Earnings Summary

Revenue
$1.23Mn
Net Profits
$-14.44Mn
Net Profit Margins
-1170.34%

Highlights

Revenue:

ProQR Therapeutics N.V’s revenue jumped +Inf% since last year same period to $1.23Mn in the Q1 2022. On a quarterly growth basis, ProQR Therapeutics N.V has generated 416.32% jump in its revenue since last 3-months.

Net Profits:

ProQR Therapeutics N.V’s net profit fell -14.56% since last year same period to $-14.44Mn in the Q1 2022. On a quarterly growth basis, ProQR Therapeutics N.V has generated 20.74% jump in its net profits since last 3-months.

Net Profit Margins:

ProQR Therapeutics N.V’s net profit margin jumped NaN% since last year same period to -1170.34% in the Q1 2022. On a quarterly growth basis, ProQR Therapeutics N.V has generated 84.65% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the ProQR Therapeutics N.V post its latest quarter earnings

EPS Estimate Current Quarter
-0.22
EPS Estimate Current Year
-0.22

Highlights

EPS Estimate Current Quarter:

ProQR Therapeutics N.V’s earning per share (EPS) estimates for the current quarter stand at -0.22 - a 8.33% jump from last quarter’s estimates.

EPS Estimate Current Year:

ProQR Therapeutics N.V’s earning per share (EPS) estimates for the current year stand at -0.22.

Key Ratios

Key ratios of the ProQR Therapeutics N.V post its Q1 2022 earnings

Earning Per Share (EPS)
-0.2
Return on Assets (ROA)
-0.23
Return on Equity (ROE)
-0.61
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

ProQR Therapeutics N.V’s earning per share (EPS) jumped 20% since last year same period to -0.2 in the Q1 2022. This indicates that the ProQR Therapeutics N.V has generated 20% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. ProQR Therapeutics N.V’s return on assets (ROA) stands at -0.23.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. ProQR Therapeutics N.V’s return on equity (ROE) stands at -0.61.

Dividend Per Share (DPS):

ProQR Therapeutics N.V declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-03-31
-0.24
-0.2
16.67%

Company Information

ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Based on its unique proprietary RNA repair platform technologies, the Company is growing its pipeline with patients and loved ones in mind.

Organisation
ProQR Therapeutics N.V
Headquarters
Leiden, Zuid Holland, Netherlands
Employees
1.5K
Industry
Health Technology
CEO
Daniel De Boer